GeoVax Labs Reports No Revenue and Continued Net Loss in Q1 2026

GeoVax Labs, Inc. has reported its financial results for the first quarter of 2026, revealing a significant decline in revenue and a continued net loss. The company reported no revenue for the three months ended March 31, 2026, compared to $1.6 million in the same period of 2025, primarily due to the termination of a government contract with the Biomedical Advanced Research and Development Authority (BARDA). Operating expenses decreased to $5.3 million from $7.0 million year-over-year, driven by reduced research and development costs and lower general and administrative expenses. The net loss for the quarter was $5.3 million, a slight improvement from a loss of $5.4 million in the prior year.

In terms of financial position, GeoVax's total assets decreased to $2.98 million as of March 31, 2026, down from $6.34 million at the end of 2025. Cash and cash equivalents also fell significantly to $1.27 million from $3.09 million, reflecting the company's ongoing cash burn. Current liabilities increased to $2.29 million from $1.94 million, primarily due to higher accounts payable. The company's stockholders' equity dropped to $493,770, down from $3.83 million at the end of 2025, indicating a challenging financial environment.

Strategically, GeoVax is focusing on advancing its vaccine candidates, particularly GEO-MVA, which is intended for mpox and smallpox. The company plans to initiate a pivotal Phase 3 clinical trial for GEO-MVA in the second half of 2026, following regulatory guidance from the European Medicines Agency. Additionally, GeoVax is preparing for a Phase 2 trial of its Gedeptin therapy for head and neck cancers, expected to start in 2027. The company is also developing a next-generation COVID-19 vaccine, GEO-CM04S1, which is currently in Phase 2 trials.

Operationally, GeoVax's workforce has expanded, with the number of issued and outstanding shares increasing to 2.82 million as of March 31, 2026, from 1.73 million at the end of 2025. The company has engaged in several financing activities, including a registered direct offering and warrant exercises, which provided approximately $1.72 million in net cash during the quarter. However, management has expressed concerns about the company's ability to continue as a going concern, emphasizing the need for additional funding to support ongoing operations and development activities.

Looking ahead, GeoVax anticipates continued losses as it progresses its clinical programs and seeks regulatory approvals. The company plans to pursue additional capital through various means, including public or private equity financing and government grants. While management believes it can secure the necessary funding, uncertainties remain regarding the timing and availability of such resources, which could impact the company's future operations and development plans.